Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: A type i isobolographic analysis for non-parallel dose-response relationship curves

Advances in Medical Sciences

Volumn 55, Issue 1, 2010, Pages 43-52

  Luszczki, J J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

carbamazepine; isobolographic analysis; maximal electroshock; pharmacodynamic pharmacokinetic interaction; pregabalin

Indexed keywords

CARBAMAZEPINE; PREGABALIN; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTRIC SHOCK; FOCAL EPILEPSY; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; SKELETAL MUSCLE; TONIC CLONIC SEIZURE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG INTERACTION; SEIZURES;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ELECTROSHOCK; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; SEIZURES;

EID: 77954486822     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-010-0005-8     Document Type: Article

References (52)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-319
2. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia. 2004;45 Suppl 6:19-27.
3. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005 Dec;46(12):1926-1936
4. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003 May 27;60(10):1631-1637
5. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse. 2002 Sep 1;45(3):171-190
6. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003 Jul;12(5):300-306
7. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006 Feb 23;1075(1):68-80.
8. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-476
9. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 Feb;73(2):137-150
10. Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, Taylor CP. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006 Mar;68(3):189-205.
11. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002 Jun;50(1-2):105-123
12. Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991 Mar;8(2):79-94.
13. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949 Jun;96(2):99-113.
14. Kozinska J, Sawicka KM, Zadrozniak A, Wojda E, Andres-Mach M, Dudra-Jastrzebska M, Luszczki JJ. Indapamide enhances the protective action of carbamazepine, phenobarbital, and valproate against maximal electroshockinduced seizures in mice. Adv Med Sci. 2009;54(1):66-74.
15. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ. Isobolographic analysis of interactions between 1-methyl- 1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshockinduced seizure model. Eur J Pharmacol. 2009 Jan 14;602(2-3):298-305.
16. Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol. 2009 Feb;379(2):163-179
17. Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):105-114
18. Luszczki JJ. Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel doseresponse relationship curves. Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):483-492
19. Luszczki JJ, Czuczwar SJ. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):434-446
20. Luszczki JJ, Krzyzanowski M, Swiader MJ. Interaction of tiagabine with valproate in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. Adv Med Sci. 2009;54(1):75-81.
21. Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a threedimensional isobolographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):51-64.
22. Tallarida RJ. Interactions between drugs and occupied receptors. Pharmacol Ther. 2007 Jan;113(1):197-209.
23. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006 Oct;319(1):1-7.
24. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):169-181
25. Boissier JR, Tardy J, Diverres JC. Une nouvelle méthode simple pour explorer l'action 'tranquilisante': le test de la cheminée. Med Exper. (Basel) 1960, 3:81-84.
26. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature. 1986 Jun 26-Jul 2;321(6073):864-866
27. Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology. 2003 Oct;28(10):1817-1830
28. Luszczki JJ, Wojcik-Cwikla J, Andres MM, Czuczwar SJ. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology. 2005 May;30(5):958-973
29. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol. 1979 Fall;1(3):233-236
30. Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953 Mar;107(3):385-393
31. Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther. 1984 Jan;228(1):1-12.
32. Luszczki JJ, Czuczwar SJ. Dose-response relationship analysis of vigabatrin doses and their antinociceptive effects in the hot-plate test in mice. Pharmacol Rep. 2008 May-Jun;60(3):409-414
33. Luszczki JJ, Kołacz A, Wojda E, Czuczwar M, Przesmycki K, Czuczwar SJ. Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice: an isobolographic analysis. Pharmacol Rep. 2009 May- Jun;61(3):459-467
34. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-18
35. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs. 2005;19(3):265-72; discussion 273-274
36. Macdonald RL, Greenfield LJ Jr. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol. 1997 Apr;10(2):121-128
37. Schachter SC. Tricyclic anticonvulsants: mechanisms of action. Epilepsy Behav. 2002 Jun;3(3S):S7-S8.
38. Stefani A, Spadoni F, Bernardi G. Voltageactivated calcium channels: targets of antiepileptic drug therapy? Epilepsia. 1997 Sep;38(9):959-965
39. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia. 1998 Oct;39(10):1054-1063
40. Kawata Y, Okada M, Murakami T, Kamata A, Zhu G, Kaneko S. Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release. Br J Pharmacol. 2001 Jun;133(4):557-567
41. Skerritt JH, Johnston GA, Chow SC. Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies. Epilepsia. 1983 Oct;24(5):643-650
42. Weir RL, Padgett W, Daly JW, Anderson SM. Interaction of anticonvulsant drugs with adenosine receptors in the central nervous system. Epilepsia. 1984 Aug;25(4):492-498
43. Marangos PJ, Weiss SR, Montgomery P, Patel J, Narang PK, Cappabianca AM, Post RM. Chronic carbamazepine treatment increases brain adenosine receptors. Epilepsia. 1985 Sep-Oct;26(5):493-498
44. Fujiwara Y, Sato M, Otsuki S. Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology (Berl). 1986;90(3):332-335
45. Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia. 2002 Sep;43(9):956-963
46. Łuszczki J, Swiader M, Czuczwar M, Kiś J, Czuczwar SJ. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol Biochem Behav. 2003 May;75(2):319-327
47. Cadart M, Marchand S, Pariat C, Bouquet S, Couet W. Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacintheophylline convulsant interaction in rats. Pharm Res. 2002 Feb;19(2):209-214
48. Bartoszyk GD, Meyerson N, Reimann W, Satzinger G, von Hodenberg A. Gabapentin. In: Meldrum BS, Porter RJ, editors. New anticonvulsant drugs. London: John Libbey; c1986. p. 147-163
49. Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res. 1997 Jul;28(1):63-72.
50. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007 Jan;4(1):75-83.
51. Leniger T, Isbruch K, von den Driesch S, Diener HC, Hufnagel A. Seizure-associated headache in epilepsy. Epilepsia. 2001 Sep;42(9):1176-1179
52. Nair DR, Najm I, Bulacio J, Lüders H. Painful auras in focal epilepsy. Neurology. 2001 Aug 28;57(4):700-702